KRYS
Price
$134.94
Change
-$2.23 (-1.63%)
Updated
May 9, 03:32 PM (EDT)
Capitalization
3.95B
94 days until earnings call
SNDX
Price
$11.01
Change
+$1.02 (+10.21%)
Updated
May 8 closing price
Capitalization
859.61M
94 days until earnings call
Ad is loading...

KRYS vs SNDX

Header iconKRYS vs SNDX Comparison
Open Charts KRYS vs SNDXBanner chart's image
Krystal Biotech
Price$134.94
Change-$2.23 (-1.63%)
Volume$400
Capitalization3.95B
Syndax Pharmaceuticals
Price$11.01
Change+$1.02 (+10.21%)
Volume$3.61M
Capitalization859.61M
KRYS vs SNDX Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. SNDX commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Hold and SNDX is a Buy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (KRYS: $137.17 vs. SNDX: $11.01)
Brand notoriety: KRYS and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 163% vs. SNDX: 169%
Market capitalization -- KRYS: $3.95B vs. SNDX: $859.61M
KRYS [@Biotechnology] is valued at $3.95B. SNDX’s [@Biotechnology] market capitalization is $859.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, both KRYS and SNDX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 4 TA indicator(s) are bullish while SNDX’s TA Score has 5 bullish TA indicator(s).

  • KRYS’s TA Score: 4 bullish, 6 bearish.
  • SNDX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SNDX is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а -17.21% price change this week, while SNDX (@Biotechnology) price change was -20.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.04%. For the same industry, the average monthly price growth was +9.92%, and the average quarterly price growth was -14.09%.

Reported Earning Dates

KRYS is expected to report earnings on Aug 11, 2025.

SNDX is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (-6.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($3.95B) has a higher market cap than SNDX($860M). KRYS YTD gains are higher at: -12.441 vs. SNDX (-16.717). KRYS has higher annual earnings (EBITDA): 110M vs. SNDX (-313.82M). KRYS (598M) and SNDX (583M) have equal amount of cash in the bank . KRYS has less debt than SNDX: KRYS (7.26M) vs SNDX (346M). KRYS has higher revenues than SNDX: KRYS (291M) vs SNDX (23.7M).
KRYSSNDXKRYS / SNDX
Capitalization3.95B860M460%
EBITDA110M-313.82M-35%
Gain YTD-12.441-16.71774%
P/E Ratio33.45N/A-
Revenue291M23.7M1,228%
Total Cash598M583M103%
Total Debt7.26M346M2%
FUNDAMENTALS RATINGS
KRYS vs SNDX: Fundamental Ratings
KRYS
SNDX
OUTLOOK RATING
1..100
576
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
85
Overvalued
PROFIT vs RISK RATING
1..100
33100
SMR RATING
1..100
6794
PRICE GROWTH RATING
1..100
8591
P/E GROWTH RATING
1..100
963
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (73) in the Pharmaceuticals Major industry is in the same range as SNDX (85) in the Biotechnology industry. This means that KRYS’s stock grew similarly to SNDX’s over the last 12 months.

KRYS's Profit vs Risk Rating (33) in the Pharmaceuticals Major industry is significantly better than the same rating for SNDX (100) in the Biotechnology industry. This means that KRYS’s stock grew significantly faster than SNDX’s over the last 12 months.

KRYS's SMR Rating (67) in the Pharmaceuticals Major industry is in the same range as SNDX (94) in the Biotechnology industry. This means that KRYS’s stock grew similarly to SNDX’s over the last 12 months.

KRYS's Price Growth Rating (85) in the Pharmaceuticals Major industry is in the same range as SNDX (91) in the Biotechnology industry. This means that KRYS’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for KRYS (96) in the Pharmaceuticals Major industry. This means that SNDX’s stock grew significantly faster than KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSSNDX
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 10 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LUSIX10.350.17
+1.67%
Lazard US Systematic Small Cap Eq Ins
MERAX14.64N/A
N/A
Madison Mid Cap A
ACERX9.92N/A
N/A
Invesco Equity and Income C
SECAX10.07N/A
N/A
SEI Small Cap II A (SIIT)
TGRGX6.99N/A
N/A
Transamerica International Focus I

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
+10.21%
IDYA - SNDX
50%
Loosely correlated
+1.96%
ETNB - SNDX
50%
Loosely correlated
+1.56%
KYMR - SNDX
49%
Loosely correlated
+5.70%
NGNE - SNDX
47%
Loosely correlated
+8.23%
RGNX - SNDX
47%
Loosely correlated
-1.24%
More